Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors Stephen John RalphMaxwell J. Reynolds Review Article Open access 17 August 2022 Pages: 527 - 542
Invariant NKT cells metabolically adapt to the acute myeloid leukaemia environment Victoria StavrouLivingstone FultangCarmela De Santo Original Article Open access 13 August 2022 Pages: 543 - 560
Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer David DoraChristopher RivardBalazs Dome Original Article 17 August 2022 Pages: 561 - 578
Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma Caroline LaheurteEvan SeffarOlivier Adotevi Original Article 21 August 2022 Pages: 579 - 589
Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study Kenji SawaIzumi SatoKoji Kawakami Original Article 22 August 2022 Pages: 591 - 598
Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management Zaoqu LiuHui XuXinwei Han Original Article 23 August 2022 Pages: 599 - 615
Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer Peng WuZhihui ZhangJie He Original Article Open access 24 August 2022 Pages: 617 - 631
PD-1+ mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy Jun LiGang PengLiangliang Shi Original Article Open access 26 August 2022 Pages: 633 - 645
Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes Dafeng XuYu WangJinfang Zheng Original Article 29 August 2022 Pages: 647 - 664
Correction to: Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes Dafeng XuYu WangJinfang Zheng Correction 22 September 2022 Pages: 665 - 665
Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy Camilla Rydberg MillrudAdnan DeronicDavid Liberg Original Article 29 August 2022 Pages: 667 - 678
Single-cell and spatial transcriptome analyses revealed cell heterogeneity and immune environment alternations in metastatic axillary lymph nodes in breast cancer Xiaofan MaoDan ZhouWei Luo Original Article 30 August 2022 Pages: 679 - 695
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial Alexandra M. AdamsElizabeth L. CarpenterGeorge E. Peoples Original Article 01 September 2022 Pages: 697 - 705
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression Tehila AzoulayIlana SlouzkyShimrit Ringelstein-Harlev Original Article 01 September 2022 Pages: 707 - 718
PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model Xin HuYifang ShuiXiao-Kang Li Original Article 02 September 2022 Pages: 719 - 731
Detecting monocyte trafficking in an animal model of glioblastoma using R2* and quantitative susceptibility mapping Runze YangA. Max HamiltonJeff F. Dunn Original Article 04 October 2022 Pages: 733 - 742
Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis Lili YinYu Wang Original Article 01 November 2022 Pages: 743 - 758
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer Maud RijndersDebbie G. J. RobbrechtReno Debets Research Report Open access 17 August 2022 Pages: 759 - 767
TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects Shance LiChaoting ZhangZheming Lu Research Report 21 August 2022 Pages: 769 - 774
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma Guru P. SonpavdeBenjamin Louis MaughanPetros Grivas Research Report 23 August 2022 Pages: 775 - 782
The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study Chongwu LiJunqi WuChang Chen Research Report 03 September 2022 Pages: 783 - 794
Correction to: The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study Chongwu LiJunqi WuChang Chen Correction 20 September 2022 Pages: 795 - 795
